Takeda selects former CRISPR Therapeutics CMO to lead oncology unit; Emile Nuwaysir out at Ensoma
→ A spokesperson for Takeda tells Peer Review that PK Morrow succeeded Chris Arendt as head of oncology on Jan. 29. A few weeks ago we told you about Morrow’s resignation as CMO of CRISPR Therapeutics, and a replacement has not been named at Vertex’s Casgevy partner. Morrow held a number of positions over a decade at Amgen, including VP and global therapeutic area head of hematology, GI oncology, GU oncology and bone diseases. Arendt vaulted to CSO and head of research last fall at the Japanese pharma, which will elevate Milano Furuta to CFO in April.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.